NO.1 诺诚健华和Zenas就三款自免管线达成授权许可合作 诺诚健华和Zenas BioPharma公司联合宣布,双方达成授权许可协议,Zenas将获得奥布替尼在多发性硬化领域的全球开发和商业化权益,以及奥布替尼在非肿瘤的其他治疗领域的开发与商业化权益。Zenas还获得两款临床前分子(一款新型口服IL-17 AA/AF抑制剂和一款透脑性口服TYK2抑制剂)的相关权益。 点评:此次战略合作将...
Source LinkNO.1 诺诚健华和Zenas就三款自免管线达成授权许可合作 诺诚健华和Zenas BioPharma公司联合宣布,双方达成授权许可协议,Zenas将获得奥布替尼在多发性硬化领域的全球开发和商业化权益,以及奥布替尼在非肿瘤的其他治疗领域的开发与商业化权益。Zenas还获得两款临床前分子(一款新型口服IL-17 AA/AF抑制剂和一款透脑性口服TYK2抑制剂)的相关权益。 点评:此次战略合作将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.